This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ASCO '13: More Data on Bristol's Immune-Boosting Melanoma Drug

Stocks in this article: BMY MRK RHHBY

CHICAGO ( TheStreet) -- Bristol-Myers Squibb's (BMY) immune system-boosting drug nivolumab produced long-lasting tumor shrinkage patients with advanced melanoma, according to updated results from an early-stage study.

The response to Nivolumab was three times better than what's typically seen with Bristol-Myers' first-generation melanoma drug Yervoy, approved in 2011.

Nivolumab belongs to a new class of drugs that work by dismantling a cloaking mechanism used by cancer cells to hide from a patient's immune system. Bristol-Myers and Merck (MRK) are each developing drugs that target this PD-1 receptor on T cells, while Roche (RHHBY) is working on a similar drug known as an anti-PDL-1 antibody.

The potent, tumor-killing efficacy of these drugs across many different types of tumors -- lung, kidney, breast as well as skin cancer -- is generating a lot of buzz at this year's American Society of Clinical Oncology (ASCO) annual meeting.

Yervoy and nivolumab could generate peak sales of $6 billion for Bristol-Myers, analysts and investor surveys indicate. The blockbuster potential for this new crop of cancer immunotherapy has been a big contributor to the 41% increase in Bristol-Myers' stock price this year. Bristol-Myers shares closed Friday at $46.01.

More data on Merck's drug, known as lambrolizumab, will be released Sunday morning at the ASCO meeting.

In the phase I study, 107 patients with advanced, stage IV melanoma were treated with five different doses of Bristol-Myers' nivolumab. Twenty-five percent of the patients had already been treated with three or more prior therapies, and 63% had two or more.

Overall, 31% of the nivolumab-treated patients reported clinically meaningful tumor shrinkage. The median overall survival across all nivolumab doses was 16.8 months and 43% of patients were still alive at two years of follow up.

The study lacked a control arm so the nivolumab survival data cannot be compared directly against another drug or a placebo. However, Yervoy typically produces tumor shrinkage rates of 5-10% and a median overall survival of 10 months in patients with advanced melanoma.

Seventeen melanoma patients in the study were treated with a 3 mg of nivolumab, which Bristol-Myers has already identified as the most effective dose to use in phase III studies already underway. The overall response rate in these patients was 41% with a median overall survival of 20.3 months.

Long-term follow-up results from early-stage studies of nivolumab in non-small cell lung cancer and kidney cancer are being presented on Monday at the ASCO annual meeting.

Bristol-Myers is also investigating the combination of nivolumab and Yervoy. In one early-stage study, the two-drug combination produced a tumor shrinkage rate of 50 percent in melanoma patients.

Merck and Roche will also be presenting updates results on their respective PD-1 and anti-PDL-1 drugs during the ASCO meeting.

-- Reported by Adam Feuerstein in Chicago.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs